

2026 ANNUAL MEETING



Poster 2: Ovarian cancer patients with intellectual and developmental disabilities and Alzheimer's disease and related disorders have worse survival and are less likely to receive guideline-adherent cancer care

Presenting Author: Lila Marshall, MD, University of California Irvine

Topic

Financial Toxicity and Disparities

Objectives

Cancer patients with intellectual and developmental disabilities (IDD) and Alzheimer's disease and related disorders (ADRD) are diagnosed at later stages, are less likely to receive aggressive treatment if at all, and have worse survival. Data on gynecologic cancer patients are scarce. This study explored cancer outcomes and treatment patterns for ovarian cancer patients with IDD and ADRD.

Methods

Ovarian cancer cases from the California Cancer Registry (CCR) from 1996-2014 were linked with Office of Statewide Health Planning and Development (OSHPD) data. Inclusion criteria: age ≥ 18 , diagnosis of ovarian cancer. Exclusion criteria: incomplete clinical information, other cancer type. ICD-9 diagnosis codes were used to identify cases of IDD and ADRD. Dichotomous variables were created for adherence to National Comprehensive Cancer Network (NCCN) guidelines for surgery and overall treatment plan. A Cox-proportional hazards model was used to evaluate the effect of predictors on disease-specific survival (DSS), generating adjusted hazards ratios (aHR) with 95% confidence intervals (CI).

Results

Total 27780 ovarian cancer patients had records in CCR and OSHPD; 611 (2.2%) had ADRD and 87 (0.3%) had IDD. Patient characteristics are in table 1. Patients with ADRD had lower adherence to surgery guidelines compared to those without; 31.26% vs 55.22% ($p < 0.0001$). Adherence to overall treatment guidelines was 16.53% vs 39.25% ($p < 0.0001$). aHR for DSS in patients with vs without ADRD was 1.24 (95% CI 1.10-1.40, $p = 0.0006$). Patients with IDD had lower adherence to surgery guidelines compared to those without IDD; 39.08% vs 54.74% ($p = 0.0034$). Overall treatment plan adherence was also lower; 17.24% vs 38.82% ($p < 0.0001$). aHR for DSS in patients with vs without IDD was 2.07 (95% CI 1.45-2.95, $p < 0.0001$).

Conclusions

Ovarian cancer patients with IDD and ADRD were less likely to receive NCCN-adherent care and had worse survival. Notably, the patients with IDD had demographic and clinical characteristics that should have conferred survival benefit; younger age, less serous histology, lower stage.

Uploaded File(s)

Abstract Table or Graph

Table 1. Demographic and cancer characteristics comparing patients with and without ADRD, IDD

		Without ADRD (n=27780) (%)	With ADRD (n=611) (%)	Total (n)	χ^2 test p-value	With IDD (n=87) (%)	Total (n)	χ^2 test p-value
Age (years)	18-44	3710 (13.66)	3 (0.49)	3713	p <0.0001	26 (29.89)	3713	p <0.0001
	45-54	5970 (21.97)	12 (1.96)	5982		26 (29.89)	5982	
	55-64	6704 (24.68)	33 (5.4)	6737		23 (26.44)	6737	
	≥65	10785 (39.7)	563 (92.14)	11348		12 (13.79)	11348	
Race and ethnicity	Non-Hispanic White	17619 (64.85)	439 (71.85)	18058	p <0.0001	49 (56.32)	18058	p 0.0453
	Non-Hispanic Black	1303 (4.8)	42 (6.87)	1345		9 (10.34)	1345	
	Hispanic	4883 (17.97)	84 (13.75)	4967		21 (24.14)	4967	
	Asian/Pacific Islander	3194 (11.76)	41 (6.71)	3235		7 (8.05)	3235	
	Other	170 (0.63)	5 (0.82)	175		1 (1.15)	175	
Charlson Comorbidity Index score	0	14187 (52.22)	40 (6.55)	14227	p <0.0001	30 (34.48)	14227	p 0.0074
	1	6658 (24.51)	143 (23.4)	6801		28 (32.18)	6801	
	2+	6324 (23.28)	428 (70.05)	6752		29 (33.33)	6752	
Stage	I	6481 (23.85)	108 (17.35)	6587	p <0.0001	28 (32.18)	6587	p 0.254
	II	2269 (8.35)	53 (8.67)	2322		6 (6.9)	2322	
	III	10430 (38.39)	210 (34.37)	10640		27 (31.03)	10640	
	IV	7989 (29.4)	242 (39.61)	8231		26 (29.89)	8231	
Histology	Serous	11873 (43.7)	222 (36.33)	12095	p <0.0001	20 (22.99)	12095	p 0.0007
	Mucinous	1748 (6.43)	22 (3.6)	1770		9 (10.34)	1770	
	Endometrioid	3048 (11.22)	53 (8.67)	3101		19 (21.84)	3101	
	Clear cell	1685 (6.2)	17 (2.78)	1702		4 (4.6)	1702	
	Adenocarcinoma	2821 (10.38)	108 (17.35)	2927		11 (12.64)	2927	
	Other	5994 (22.06)	191 (31.26)	6185		24 (27.59)	6185	
Treatment adherence - surgery	Not adherent	12166 (44.78)	420 (68.74)	12586	p <0.0001	53 (60.92)	12586	p 0.0034
	Adherent	15003 (55.22)	191 (31.26)	15194		34 (39.08)	15194	
Overall treatment plan adherence	Not adherent	16504 (60.75)	510 (83.47)	17014	p <0.0001	72 (82.76)	17014	p <0.0001
	Adherent	10665 (39.25)	101 (16.53)	10766		15 (17.24)	10766	